<unk>  is approved for use in a broad population of HIV-infected patients. It can be used to treat HIV-infected adults who have never taken HIV therapy (treatment-naïve) and HIV-infected adults who have previously taken HIV therapy (treatment-experienced), including those who have been treated with other integrase strand transfer inhibitors. Tivicay is also approved for children ages 12 years and older weighing at least 40 kilograms (kg) who are treatment-naïve or treatment-experienced but have not previously taken other integrase strand transfer inhibitors. In the European Union it is indicated, in combination with other anti-retroviral medicinal products, for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children above six years of age. In June 2020, the indication for<unk>  in the US was updated to include children at least four weeks old and weighing at least 3 kg (6.61 pounds).
Dolutegravir
Saquinavir
Elvitegravir
Maribavir
Entecavir
Fosamprenavir
Remdesivir
Fostemsavir